165 related articles for article (PubMed ID: 5024593)
1. [Further clinical experiences with ornithine aspartate in liver diseases].
Wotzka R; Weber D
Ther Ggw; 1972 Mar; 111(3):400-12. PubMed ID: 5024593
[No Abstract] [Full Text] [Related]
2. [On the therapy of liver diseases with ornithine aspartate].
Melzer H; Weber D; Wotzka R
Med Klin; 1969; 64(35):1541-4. PubMed ID: 5354488
[No Abstract] [Full Text] [Related]
3. [Experiences with ornithine-aspartate in liver diseases].
Aschke J
Med Welt; 1969 Mar; 12():657-62. PubMed ID: 5767441
[No Abstract] [Full Text] [Related]
4. [Clinical experiences in liver diseases (specially in patients with fatty liver due to alcoholism and food poisoning) under monotherapy with ornithine aspartate].
Hunold W
Z Allgemeinmed; 1973 Apr; 49(10):469-72. PubMed ID: 4580434
[No Abstract] [Full Text] [Related]
5. [Clinical study on the effects of L-ornithine-L-aspartate on liver dysfunction].
Kosozu K
Iryo; 1966 Apr; 20(4):339-46. PubMed ID: 5974192
[No Abstract] [Full Text] [Related]
6. [Personal experiences in the treatment of internal diseases with ornithine aspartate].
Perinović M; Robović Z; Grujić M; Ljubojević S
Med Arh; 1969; 23(3):29-32. PubMed ID: 5200044
[No Abstract] [Full Text] [Related]
7. [Betaine aspartate in the hepato-digestive domain].
Cachin M; Pergola F
Sem Ther; 1966 Oct; 42(8):423-4. PubMed ID: 5994378
[No Abstract] [Full Text] [Related]
8. [Use of ornithine carbamoyltransferase in the treatment of liver diseases].
Caruso N; De Jacobis M; Roccato M; Sequino A; Sgoifo B; Tinello M
Clin Ter; 1984 Jul; 110(1):37-44. PubMed ID: 6237844
[No Abstract] [Full Text] [Related]
9. [Clinical investigation of silymarin in chronic liver diseases (author's transl)].
Realini S; Gonvers JJ; Hofstetter JR
Schweiz Rundsch Med Prax; 1975 May; 64(19):595-8. PubMed ID: 51497
[No Abstract] [Full Text] [Related]
10. [Our clinical experience with ornithine aspartate].
Szirmai E
Minerva Med; 1971 Jun; 62(47):2376-82. PubMed ID: 5087700
[No Abstract] [Full Text] [Related]
11. [Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
Seki S
Iryo; 1966 Apr; 20(4):354-63. PubMed ID: 5974194
[No Abstract] [Full Text] [Related]
12. [Influence of ornithine aspartate on the experimentally induced hyperammoniemia. Clinico-experimental study].
Henglein-Ottermann D
Ther Ggw; 1976 Sep; 115(9):1504-18. PubMed ID: 968783
[No Abstract] [Full Text] [Related]
13. [Clinical experience report on Hepavis].
Menninger U; Menninger W
Med Welt; 1980 Oct; 31(42):1519-21. PubMed ID: 7453534
[No Abstract] [Full Text] [Related]
14. [Clinical experimentation with Aïcamine in hepatic insufficiency].
Négret JP
Bord Med; 1972 Apr; 5(8):973-6. PubMed ID: 5053280
[No Abstract] [Full Text] [Related]
15. [Effects of treatment with nucleotides and aspartic acid in chronic liver diseases].
Iencica R
Med Interna (Bucur); 1972 Dec; 24(12):1449-53. PubMed ID: 4655566
[No Abstract] [Full Text] [Related]
16. [Hepatoprotective drugs. Clinical results of the use of a sulfhydryl-methylating preparation].
Rapino P; Marulli R; Rapex G; Della Lunga S; Sabatino P
Minerva Med; 1982 Oct; 73(40):2853-60. PubMed ID: 7133498
[No Abstract] [Full Text] [Related]
17. [Thiomesterone and liver function].
Pickert H
Med Klin; 1968 Aug; 63(31):1222-6. PubMed ID: 5719699
[No Abstract] [Full Text] [Related]
18. [Clinical experience with silymarin in the treatment of chronic liver disease(author's transl)].
Reutter FW; Haase W
Schweiz Rundsch Med Prax; 1975 Sep; 64(36):1145-51. PubMed ID: 1099576
[No Abstract] [Full Text] [Related]
19. [Clinical study of the effect of the administration of cathergen preparation in patients with chronic hepatic lesions].
Maleev A; Tsvetkova V; Krŭstev Z; Kostova N; Lukanov L
Vutr Boles; 1985; 24(5):39-43. PubMed ID: 4090451
[No Abstract] [Full Text] [Related]
20. [Protection of the liver and liver therapy with Hepamerz].
Heynen U
Z Allgemeinmed; 1970 Jan; 46(2):87-8. PubMed ID: 5439291
[No Abstract] [Full Text] [Related]
[Next] [New Search]
